Markets

Home  /  Investors

Investing in XVIVO

Company overview

XVIVO is a world leader in organ transplantation and the only MedTech company dedicated to extending the life of all major organs. Our services and innovative machine perfusion technologies allow transplantation teams to preserve, transport and assess donor organs outside the body, ultimately saving more lives. We are guided by our purpose, “Nobody should die waiting for a new organ,” and strive every day to enable clinicians and researchers to push the boundaries of organ transplantation. As we do so, we are committed to delivering long-term value to healthcare systems and our shareholders.

XVIVO as an investment

High growth potential, contributing to saving more lives in a rapidly changing market

Market potential for machine perfusion is 10x larger than current standard of care

XVIVO’s offer increases the availability of transplantable organs

History of continuous profitable growth and high margins

Future-secured product portfolio and track record of successfully bringing innovation to market

Latest press releases

5 Sep, 2025
Nomination Committee of XVIVO Perfusion AB (publ)
28 Jul, 2025
Delay in CE approval for XVIVO’s perfusion solution for heart preservation
21 Jul, 2025
First patient enrolled in US PRESERVE CAP study for XVIVO Heart Assist Transport device
11 Jul, 2025
Interim report January-June 2025
11 Jul, 2025
Interim report January-June 2025
24 Apr, 2025
Interim report January-March 2025
2 Apr, 2025
Annual Report 2024
28 Jan, 2025
Year-end report 2024

Financial calendar

Interim Reports and Year End Reports are always released at 7:30 AM CET, with the Earnings Call scheduled for the same day at 2:00 PM CET.

Investor relations

Kristoffer Nordström

Kristoffer Nordström, CFO & Investor Relations

Fill out the form to watch the video